Prime editing can efficiently rewrite the genetic mutation causing sickle cell disease, in haematopoietic stem cells from patients.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$79.00 per year
only $6.58 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Everette, K. A. et al. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-023-01026-0 (2023).
Anzalone, A. V. et al. Nature 576, 149–157 (2019).
Newby, G. A. et al. Nature 595, 295–302 (2021).
Nelson, J. W. et al. Nat. Biotechnol. 40, 402–410 (2021); author correction 40, 432 (2022).
Chen, P. J. et al. Cell 184, 5635–5652.e29 (2021).
DeWitt, M. A. et al. Sci. Transl Med. 8, 360ra134 (2016).
Kim, D. Y., Moon, S. B., Ko, J.-H., Kim, Y.-S. & Kim, D. Nucleic Acids Res. 48, 10576–10589 (2020).
Zeng, J. et al. Nat. Med. 26, 535–541 (2020).
Frangoul, H. et al. N. Engl. J. Med. 384, 252–260 (2021).
Magnani, A. et al. Haematologica 105, 1240–1247 (2020).
Yao, S. Graphite Bio announces voluntary pause of phase 1/2 CEDAR study of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease (Graphite Bio, 5 January 2023); https://go.nature.com/3MZNnnA
Levesque, S. et al. Nat. Commun. 13, 5909 (2022).
Anzalone, A. V. et al. Nat. Biotechnol. 40, 731–740 (2022).
Yarnall, M. T. N. et al. Nat. Biotechnol. 41, 500–512 (2022).
Li, C. et al. Blood https://doi.org/10.1182/blood.2022018252 (2023).
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Levesque, S., Bauer, D.E. Gene correction for sickle cell disease hits its prime. Nat. Biomed. Eng 7, 605–606 (2023). https://doi.org/10.1038/s41551-023-01040-2